Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 July 2025 | Story Precious Shamase
UFS Green Campus Initiative Team
The UFS Green Campus Initiative team after being announced winners for the fourth consecutive year.

The University of the Free State (UFS) is celebrating an outstanding achievement at the 12th Annual Green Campuses Conference (GCC) 2025, where its dynamic Green Campus Initiative (GCI) team from the Qwaqwa Campus clinched the coveted Best Exhibition Award. This marks an unprecedented fourth consecutive year that the UFS has secured this prestigious accolade, highlighting its unwavering commitment to sustainability and innovation within the higher education landscape.

Hosted by Nelson Mandela University in Gqeberha, Eastern Cape, the conference was presented by the Association of College and University Housing Officers - International (ACUHO-I) under the profoundly relevant theme, Ubuntu and Environment: African Indigenous Knowledge in Sustainability. Endorsed by the Department of Higher Education and Training, the GCC serves as a pivotal platform for institutions of higher learning across South Africa to exchange vital knowledge, share best practices, and explore groundbreaking innovations in environmental sustainability and climate change mitigation.

The UFS GCI team's exhibition captivated judges and attendees alike with its exceptional creativity, innovative spirit, and profound dedication to envisioning a greener future. "The creativity, innovation, and commitment to sustainability shone through every detail of the display," remarked residential head Itumeleng Lebusho, "a true reflection of what it means to envision a greener future".

The five students who represented the institution were Amukelani Ngobeni, Minenhle Mnguni, Sinenhlanhla Mathabela, Charmaine Nokubonga Nkosi, and Thandolwethu Nyathikazi.

A cornerstone of the student-driven conference, the GCC featured three main categories: project presentations, a runway showcase, and the highly anticipated exhibition. UFS students excelled across the board, demonstrating their ingenuity in tackling real-world campus challenges with sustainable solutions.

A particularly notable project was the student-designed mobile trolley. Addressing a common predicament faced by students transporting groceries from the main gate to their residences due to campus restrictions on taxis for security reasons, the team engineered an innovative solution. This solar-powered mobile trolley, equipped with batteries and a motor, began as a prototype in 2024 and has since evolved into a testament to student-led problem-solving. While the current iteration requires a Code 8 driver's licence to operate, its potential to revolutionise campus mobility is clear.

The conference's annual theme encourages participants to devise sustainable solutions to problems faced on campus, a challenge that the UFS GCI team has embraced with remarkable success.

The UFS' consistent triumph at the GCC is a testament to the dedication and sacrifice of its students, whose forward-thinking ideas continue to push the boundaries of what is possible in campus greening. "The students worked in a way that we never imagined," expressed Desiree Motsele, Residence Head within Housing and Residence Affairs. "The ideas that they come up with are truly inspiring."

By actively participating in this significant event, the UFS is not only strengthening its commitment to creating a green campus but also fostering a healthy learning and living environment. This continued dedication prioritises sustainability, advances energy efficiency, champions resource conservation, and promotes environmental stewardship, solidifying the UFS' position as a leader in sustainable practices within South African higher education.

The Director: Student Affairs, Zoleka Dotwana, said she would like to congratulate the students on yet another gold they won at the GCI 2025. “The effort, the hard work, the commitment you have shown, has once again raised our UFS flag high. I hope the experience and the graduate attributes you have learnt in preparing your project will go a long way in providing you with great opportunities when you leave our shores. It has been an awesome journey over the four years, one that we hold dear and that will remain in the history books of our campus. Thank you for flying our flag high - Only a Kovsie knows the feeling!' said an ecstatic Dotwana.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept